MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®? FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
Mangoceuticals, Inc. (MGRX)
Company Research
Source: GlobeNewswire
The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME’ by MangoRx, Powered by Kyzatrex®? (a $498 value) for First 1,000 Subscribers Dallas, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it is offering 2 months of free ‘PRIME’ by MangoRx, Powered by Kyzatrex®? (“PRIME”) (a $498 value) for the first 1,000 male subscribers who express interest in subscribing to the oral testosterone replacement protocol. Those interested in taking advantage of this exclusive offer simply need to visit the sign-up page at https://www.mangorx.com/prime-sign-up/ and submit basic demographic information. Interested s
Show less
Read more
Impact Snapshot
Event Time:
MGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGRX alerts
High impacting Mangoceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MGRX
News
- Mangoceuticals acquires a global patent portfolio [Seeking Alpha]Seeking Alpha
- Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive CareGlobeNewswire
- Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) ProductsGlobeNewswire
- MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®? FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentGlobeNewswire
- MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthGlobeNewswire
MGRX
Sec Filings
- 4/25/24 - Form 8-K
- 4/23/24 - Form S-1
- 4/11/24 - Form 8-K
- MGRX's page on the SEC website